<p>2025 年 10 月 15 日- 下午 02:36</p>
<p><strong>纳斯达克听证会取消及持续上市</strong></p>
<p>加利福尼亚州福斯特城，2025 年 10 月 15 日（全球新闻稿）-- Apollomics Inc.（纳斯达克：APLM）（“Apollomics” 或 “公司”）是一家位于加利福尼亚的晚期临床生物制药公司，开发多种肿瘤药物候选者以应对难治性和耐药性癌症。公司此前宣布已提交申请，申请对纳斯达克证券市场（“纳斯达克”）上市资格工作人员（“工作人员”）之前发出的退市通知进行上诉，并请求在纳斯达克听证小组面前进行听证，以审查工作人员的退市决定。公司今天宣布，已于 2025 年 10 月 14 日收到纳斯达克的信函，通知 Apollomics 工作人员已确定公司符合纳斯达克的持续上市要求。因此，纳斯达克已取消其上诉听证会，公司证券将继续在纳斯达克证券市场上市和交易。</p>
<p><strong>关于 Apollomics Inc.</strong></p>
<p>Apollomics Inc.是一家创新的临床阶段生物制药公司，专注于发现和开发具有与其他治疗选项结合潜力的肿瘤治疗药物，以利用免疫系统并针对特定分子通路抑制癌症。Apollomics 的主导项目是 vebreltinib（APL-101），这是一种强效、选择性的 c-Met 抑制剂，用于治疗非小细胞肺癌和其他具有 c-Met 改变的晚期肿瘤，目前正在美国和其他国家进行第二阶段多队列临床试验。有关更多信息，请访问 www.apollomicsinc.com。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿包含根据联邦证券法，包括 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条修订版的定义构成的 “前瞻性声明”。除本新闻稿中包含的当前或历史事实声明外，所有关于 Apollomics 的战略、前景、计划、目标及 vebreltinib 开发和商业化的预期结果、关于开曼诉讼的未来程序，或对纳斯达克退市通知的上诉、回应或结果的声明均为前瞻性声明。在本新闻稿中使用的 “可能”、“应该”、“将”、“或许”、“相信”、“预期”、“打算”、“估计”、“期望”、“寻求”、“预测” 等词语及其否定形式以及其他类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含此类识别词。这些前瞻性声明基于管理层对未来事件的当前预期和假设，并基于当前可用的信息，关于未来事件的结果和时机。此外，Apollomics 提醒您，本新闻稿中包含的前瞻性声明受到未知风险、不确定性和其他因素的影响，包括在 Apollomics Inc.向美国证券交易委员会（“SEC”）提交的截至 2024 年 12 月 31 日的年度报告的 “风险因素” 标题下讨论的风险和不确定性，以及 Apollomics 向 SEC 提交或将提交的其他文件。有关这些及其他可能影响本报告中讨论的运营和预测的因素的更多信息，请参阅 Apollomics 不时向 SEC 提交的报告。前瞻性声明仅在 Apollomics 作出声明的日期有效。Apollomics 没有义务公开更新其任何前瞻性声明，以反映实际结果、新信息或未来事件、假设的变化或影响前瞻性声明的其他因素的变化，除非适用法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVME5qSTFPU00zTVRrM05qVTRJekl4TWpJM05qQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVME5qSTFPU00zTVRrM05qVTRJekl4TWpJM05qQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGNkMGM2NzQtYTQxNi00ZTMyLWE2ZWEtYmMxNTVhOWQ0ZjU2LTExMzQzMzEtMjAyNS0xMC0xNS1lbg==/tiny/Apollomics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGNkMGM2NzQtYTQxNi00ZTMyLWE2ZWEtYmMxNTVhOWQ0ZjU2LTExMzQzMzEtMjAyNS0xMC0xNS1lbg==/tiny/Apollomics-Inc-.png"/></p>
<pre><code> 投资者联系：Apollomics：Peter Lin，首席财务官 Apollomics, Inc.电话：1-650-209-4055 电子邮件：peter.lin@apollomicsinc.com
</code></pre>

APLM

<p>Apollomics Inc. 宣布在收到纳斯达克确认符合上市要求的信函后，将继续在纳斯达克证券市场上市。这是在取消关于之前退市通知的预定听证会之后的决定。Apollomics 专注于开发肿瘤治疗药物，包括其主要项目 vebreltinib，用于治疗非小细胞肺癌。该公司强调，新闻稿中的前瞻性声明受到风险和不确定性的影响</p>

<p>10/15/2025 - 02:36 PM</p>
<div class="lb-trans"><p>2025 年 10 月 15 日- 下午 02:36</p>
</div><p><strong>Nasdaq Hearing Cancellation and Continued Listing</strong></p>
<div class="lb-trans"><p><strong>纳斯达克听证会取消及持续上市</strong></p>
</div><p>FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff’s delisting determination. The Company today announced that it had received a letter from Nasdaq on October 14, 2025, notifying Apollomics the Staff had determined that the Company is in compliance with Nasdaq’s continued listing requirements. Accordingly, Nasdaq has cancelled its appeal hearing and the Company’s securities will remain listed and continue to trade on The Nasdaq Stock Market.</p>
<div class="lb-trans"><p>加利福尼亚州福斯特城，2025 年 10 月 15 日（全球新闻稿）-- Apollomics Inc.（纳斯达克：APLM）（“Apollomics” 或 “公司”）是一家位于加利福尼亚的晚期临床生物制药公司，开发多种肿瘤药物候选者以应对难治性和耐药性癌症。公司此前宣布已提交申请，申请对纳斯达克证券市场（“纳斯达克”）上市资格工作人员（“工作人员”）之前发出的退市通知进行上诉，并请求在纳斯达克听证小组面前进行听证，以审查工作人员的退市决定。公司今天宣布，已于 2025 年 10 月 14 日收到纳斯达克的信函，通知 Apollomics 工作人员已确定公司符合纳斯达克的持续上市要求。因此，纳斯达克已取消其上诉听证会，公司证券将继续在纳斯达克证券市场上市和交易。</p>
</div><p><strong>About Apollomics Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Apollomics Inc.</strong></p>
</div><p>Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com.</p>
<div class="lb-trans"><p>Apollomics Inc.是一家创新的临床阶段生物制药公司，专注于发现和开发具有与其他治疗选项结合潜力的肿瘤治疗药物，以利用免疫系统并针对特定分子通路抑制癌症。Apollomics 的主导项目是 vebreltinib（APL-101），这是一种强效、选择性的 c-Met 抑制剂，用于治疗非小细胞肺癌和其他具有 c-Met 改变的晚期肿瘤，目前正在美国和其他国家进行第二阶段多队列临床试验。有关更多信息，请访问 www.apollomicsinc.com。</p>
</div><p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib, future proceedings with respect to the Cayman Litigation, or the appeal of, response to, or outcome of the Nasdaq delisting notification, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含根据联邦证券法，包括 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条修订版的定义构成的 “前瞻性声明”。除本新闻稿中包含的当前或历史事实声明外，所有关于 Apollomics 的战略、前景、计划、目标及 vebreltinib 开发和商业化的预期结果、关于开曼诉讼的未来程序，或对纳斯达克退市通知的上诉、回应或结果的声明均为前瞻性声明。在本新闻稿中使用的 “可能”、“应该”、“将”、“或许”、“相信”、“预期”、“打算”、“估计”、“期望”、“寻求”、“预测” 等词语及其否定形式以及其他类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含此类识别词。这些前瞻性声明基于管理层对未来事件的当前预期和假设，并基于当前可用的信息，关于未来事件的结果和时机。此外，Apollomics 提醒您，本新闻稿中包含的前瞻性声明受到未知风险、不确定性和其他因素的影响，包括在 Apollomics Inc.向美国证券交易委员会（“SEC”）提交的截至 2024 年 12 月 31 日的年度报告的 “风险因素” 标题下讨论的风险和不确定性，以及 Apollomics 向 SEC 提交或将提交的其他文件。有关这些及其他可能影响本报告中讨论的运营和预测的因素的更多信息，请参阅 Apollomics 不时向 SEC 提交的报告。前瞻性声明仅在 Apollomics 作出声明的日期有效。Apollomics 没有义务公开更新其任何前瞻性声明，以反映实际结果、新信息或未来事件、假设的变化或影响前瞻性声明的其他因素的变化，除非适用法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVME5qSTFPU00zTVRrM05qVTRJekl4TWpJM05qQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU0NjI1OSM3MTk3NjU4IzIxMjI3NjA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGNkMGM2NzQtYTQxNi00ZTMyLWE2ZWEtYmMxNTVhOWQ0ZjU2LTExMzQzMzEtMjAyNS0xMC0xNS1lbg==/tiny/Apollomics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGNkMGM2NzQtYTQxNi00ZTMyLWE2ZWEtYmMxNTVhOWQ0ZjU2LTExMzQzMzEtMjAyNS0xMC0xNS1lbg==/tiny/Apollomics-Inc-.png"/></p>
<pre><code>Investor Contacts:Apollomics:Peter Lin, Chief Financial OfficerApollomics, Inc.Phone: 1-650-209-4055Email: peter.lin@apollomicsinc.com
</code></pre>
<div class="lb-trans"><pre><code> 投资者联系：Apollomics：Peter Lin，首席财务官 Apollomics, Inc.电话：1-650-209-4055 电子邮件：peter.lin@apollomicsinc.com
</code></pre>
</div>

Apollomics 宣布在听证会取消后继续在纳斯达克股票市场上市 | APLM 股票新闻